Formulary
|
Dermatology prescribing may require use of expensive unlicensed Specials Recommended by the British Association of Dermatologists for Skin Disease |
|
Several medicines in the skin chapter are available for purchase over the counter and may be appropriate for self care. Please consult the local OTC policy for more details. LSCMMG: Over The Counter (OTC) Items That Should Not Be Routinely Prescribed In Primary Care Policy |
| Dimethyl Fumarate Skilarence® |
|
Formulary
|
Tablets 30mg, 120mg The MHRA recommends that patients and their carers should be counselled on the risk of progressive multifocal leukoencephalopathy and advised to seek immediate medical attention if symptoms develop. |
 NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis |
|
| Ixekizumab Taltz® |
|
Formulary
|
Injection pre-filled pen 80mg/1ml Under expert supervision. |
|
NICE TA442: Ixekizumab for treating moderate to severe plaque psoriasis NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs |
|
| Spesolimab Spevigo® |
|
Formulary
|
Solution for infusion 450mg/7.5ml Under expert supervision. |
|
NICE TA1070: Spesolimab for treating generalised pustular psoriasis flares |
|
|
Links
Lancashire and South Cumbria Infant Feeding Network - Diagnosis and Management of Milk Allergy and Intolerance Guideline- LSCMMG: Inflammatory Bowel Disease: High Cost Drugs Commissioning Pathway
- LSCMMG: Primary Care Constipation Guidelines
- MHRA Drug Safety Update July 2021: Oral retinoid medicines (isotretinoin, alitretinoin, and acitretin): temporary monitoring advice during coronavirus (COVID-19) pandemic
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Corticosteroids: rare risk of central serous chorioretinopathy with local as well as systemic administration
- MHRA: Oral retinoids: pregnancy prevention—reminder of measures to minimise teratogenic risk
- MHRA: Topical corticosteroids: information on the risk of topical steroid withdrawal reactions
- MHRA: Topical steroids: introduction of new labelling and a reminder of the possibility of severe side effects, including Topical Steroid Withdrawal Reactions
- NHSE: National Patient Safety Alert – Steroid Emergency Card to support early recognition and treatment of adrenal crisis in adults
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people
- NICE TA1070: Spesolimab for treating generalised pustular psoriasis flares
- NICE TA442: Ixekizumab for treating moderate to severe plaque psoriasis
- NICE TA442: Ixekizumab for treating moderate to severe plaque psoriasis
- NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis
- NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis
- NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
- NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
- NICE TA701: Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal)
- NICE TA718: Ixekizumab for treating axial spondyloarthritis
- UKMI Q &A: acitretin use in renal impairment/ renal replacement therapies
UKMI Q&A: Fumaderm - What is the evidence in psoriasis